June 19, 2017 / 11:39 AM / 3 months ago

BRIEF-FDA accepts Rigel's NDA for Tavalisse

June 19 (Reuters) - Rigel Pharmaceuticals:

* FDA accepts Rigel’s New Drug Application for Tavalisse™ (fostamatinib disodium) for the treatment of chronic ITP

* Says expects action date for FDA to complete its review will be April 17, 2018, under Prescription Drug User Fee Act​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below